Dianthus Historical Financial Ratios

DNTH Stock

23.60 0.24 1.03%

Dianthus Therapeutics is recently reporting on over 83 different financial statement accounts. To analyze all of these accounts together requires a lot of time and effort. However, using these accounts to derive some meaningful and actionable indicators such as PTB Ratio of 0.3 or Days Sales Outstanding of 58.65 will help investors to properly organize and evaluate Dianthus Therapeutics financial condition quickly.

Quick Ratio Current Ratio

Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Dianthus Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.

For more detail on how to invest in Dianthus Stock please use our How to Invest in Dianthus Therapeutics guide.

About Dianthus Financial Ratios Analysis

Dianthus TherapeuticsFinancial ratios are relationships based on a company's financial information. They can serve as useful tools to evaluate Dianthus Therapeutics investment potential. Financial ratio analysis can also be defined as the process of presenting financial ratios, which are mathematical indicators calculated by comparing key financial information appearing on Dianthus financial statements. Financial ratios are useful tools that help investors analyze and compare relationships between different pieces of financial information across Dianthus Therapeutics history.

Dianthus Therapeutics Financial Ratios Chart

As of now, Dianthus Therapeutics' EV To Free Cash Flow is increasing as compared to previous years. The Dianthus Therapeutics' current Net Debt To EBITDA is estimated to increase to 2.87, while PTB Ratio is projected to decrease to 0.30.

Price To Sales Ratio Days Sales Outstanding Inventory Turnover Days Of Inventory On Hand Intangibles To Total Assets Company Equity Multiplier

Add Fundamental

Price To Sales Ratio

Price to Sales Ratio is figured by comparing Dianthus Therapeutics stock price to its revenues. An advantage to using Price to Sales ratio is that it is based on Dianthus Therapeutics sales, a figure that is much harder to manipulate than other Dianthus Therapeutics multiples. Because sales tend to be more stable P/S ratio can be a good tool for screening cyclical companies fluctuating earnings patterns. A valuation ratio that compares a company's stock price to its revenues, calculated by dividing the company's market cap by its total sales or revenue over a 12-month period.

Inventory Turnover

A ratio showing how many times a company's inventory is sold and replaced over a period, indicating the efficiency of inventory management.

Intangibles To Total Assets

The ratio of a company's intangible assets (like goodwill and patents) to its total assets.

Most ratios from Dianthus Therapeutics' fundamentals are interrelated and interconnected. However, analyzing fundamentals ratios one by one will only give a small insight into Dianthus Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamentals ratios, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Dianthus Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.

For more detail on how to invest in Dianthus Stock please use our How to Invest in Dianthus Therapeutics guide.As of now, Dianthus Therapeutics' EV To Free Cash Flow is increasing as compared to previous years. The Dianthus Therapeutics' current Net Debt To EBITDA is estimated to increase to 2.87, while PTB Ratio is projected to decrease to 0.30.

	2022	2023 (projected)
Payables Turnover	0.13	0.14
Days Of Inventory On Hand	2.1K	1.9K

Payables Turnover Days Of Inventory On Hand

Dianthus Therapeutics fundamentals Correlations

	Price To Sales Ratio	Ptb Ratio	Days Sales Outstanding	Book Value Per Share	Free Cash Flow Yield	Operating Cash Flow Per Share	Capex To Depreciation	Pb Ratio	Ev To Sales	Free Cash Flow Per Share	Roic	Inventory Turnover	Net Income Per Share	Days Of Inventory On Hand	Payables Turnover	Capex To Revenue	Cash Per Share	Pocfratio	Interest Coverage	Capex To Operating Cash Flow	Pfcf Ratio	Days Payables Outstanding	Income Quality	Roe	Ev To Operating Cash Flow	Pe Ratio
Price To Sales Ratio		0.47	0.75	0.06	0.91	-0.09	0.54	0.47	0.99	-0.11	-0.57	1.0	-0.15	-1.0	0.19	-0.48	-0.1	-0.56	-0.64	-0.32	-0.56	0.45	-0.5	-0.54	-0.57	-0.56
Ptb Ratio	0.47		0.36	-0.46	0.59	0.55	0.98	1.0	0.47	0.52	-0.81	0.47	0.51	-0.47	-0.52	-0.23	-0.65	-0.96	-0.98	0.19	-0.96	0.99	-0.44	-0.84	-0.96	-0.96
Days Sales Outstanding	0.75	0.36		-0.14	0.51	-0.08	0.43	0.36	0.83	-0.09	-0.21	0.78	-0.11	-0.76	0.15	-0.67	-0.16	-0.44	-0.5	-0.26	-0.44	0.36	0.01	-0.21	-0.46	-0.44
Book Value Per Share	0.06	-0.46	-0.14		-0.16	-0.93	-0.39	-0.46	0.02	-0.94	0.01	0.05	-0.94	-0.06	0.07	0.08	0.96	0.56	0.35	-0.75	0.56	-0.52	-0.05	0.04	0.56	0.56
Free Cash Flow Yield	0.91	0.59	0.51	-0.16		0.21	0.61	0.59	0.86	0.2	-0.68	0.89	0.15	-0.91	0.16	-0.3	-0.36	-0.69	-0.7	-0.04	-0.69	0.58	-0.67	-0.65	-0.69	-0.69
Operating Cash Flow Per Share	-0.09	0.55	-0.08	-0.93	0.21		0.48	0.55	-0.09	1.0	-0.14	-0.09	0.99	0.09	-0.16	0.06	-0.95	-0.63	-0.4	0.71	-0.64	0.6	-0.19	-0.17	-0.63	-0.64
Capex To Depreciation	0.54	0.98	0.43	-0.39	0.61	0.48		0.98	0.54	0.45	-0.77	0.54	0.43	-0.54	-0.49	-0.28	-0.57	-0.96	-0.98	0.04	-0.96	0.98	-0.48	-0.8	-0.96	-0.96
Pb Ratio	0.47	1.0	0.36	-0.46	0.59	0.55	0.98		0.47	0.52	-0.81	0.47	0.51	-0.47	-0.52	-0.23	-0.65	-0.96	-0.98	0.19	-0.96	0.99	-0.44	-0.84	-0.96	-0.96
Ev To Sales	0.99	0.47	0.83	0.02	0.86	-0.09	0.54	0.47		-0.11	-0.52	1.0	-0.15	-0.99	0.19	-0.54	-0.12	-0.56	-0.64	-0.32	-0.56	0.45	-0.42	-0.5	-0.57	-0.56
Free Cash Flow Per Share	-0.11	0.52	-0.09	-0.94	0.2	1.0	0.45	0.52	-0.11		-0.13	-0.11	1.0	0.11	-0.15	0.06	-0.96	-0.61	-0.38	0.76	-0.61	0.58	-0.16	-0.16	-0.6	-0.61
Roic	-0.57	-0.81	-0.21	0.01	-0.68	-0.14	-0.77	-0.81	-0.52	-0.13		-0.55	-0.1	0.57	0.34	0.12	0.27	0.71	0.85	0.1	0.71	-0.73	0.63	1.0	0.71	0.7
Inventory Turnover	1.0	0.47	0.78	0.05	0.89	-0.09	0.54	0.47	1.0	-0.11	-0.55		-0.15	-1.0	0.19	-0.5	-0.11	-0.56	-0.64	-0.32	-0.56	0.45	-0.47	-0.53	-0.57	-0.56
Net Income Per Share	-0.15	0.51	-0.11	-0.94	0.15	0.99	0.43	0.51	-0.15	1.0	-0.1	-0.15		0.15	-0.2	0.07	-0.94	-0.59	-0.36	0.77	-0.59	0.57	-0.11	-0.13	-0.58	-0.59
Days Of Inventory On Hand	-1.0	-0.47	-0.76	-0.06	-0.91	0.09	-0.54	-0.47	-0.99	0.11	0.57	-1.0	0.15		-0.19	0.46	0.1	0.56	0.64	0.32	0.56	-0.45	0.49	0.54	0.57	0.56
Payables Turnover	0.19	-0.52	0.15	0.07	0.16	-0.16	-0.49	-0.52	0.19	-0.15	0.34	0.19	-0.2	-0.19		-0.09	0.14	0.38	0.45	-0.28	0.39	-0.56	-0.12	0.36	0.38	0.39
Capex To Revenue	-0.48	-0.23	-0.67	0.08	-0.3	0.06	-0.28	-0.23	-0.54	0.06	0.12	-0.5	0.07	0.46	-0.09		0.06	0.28	0.32	0.17	0.28	-0.23	0.27	0.12	0.29	0.28
Cash Per Share	-0.1	-0.65	-0.16	0.96	-0.36	-0.95	-0.57	-0.65	-0.12	-0.96	0.27	-0.11	-0.94	0.1	0.14	0.06		0.73	0.55	-0.7	0.73	-0.69	0.15	0.3	0.73	0.73
Pocfratio	-0.56	-0.96	-0.44	0.56	-0.69	-0.63	-0.96	-0.96	-0.56	-0.61	0.71	-0.56	-0.59	0.56	0.38	0.28	0.73		0.95	-0.23	1.0	-0.98	0.48	0.73	1.0	1.0
Interest Coverage	-0.64	-0.98	-0.5	0.35	-0.7	-0.4	-0.98	-0.98	-0.64	-0.38	0.85	-0.64	-0.36	0.64	0.45	0.32	0.55	0.95		-0.06	0.95	-0.96	0.47	0.86	0.95	0.95
Capex To Operating Cash Flow	-0.32	0.19	-0.26	-0.75	-0.04	0.71	0.04	0.19	-0.32	0.76	0.1	-0.32	0.77	0.32	-0.28	0.17	-0.7	-0.23	-0.06		-0.24	0.25	0.24	0.09	-0.23	-0.24
Pfcf Ratio	-0.56	-0.96	-0.44	0.56	-0.69	-0.64	-0.96	-0.96	-0.56	-0.61	0.71	-0.56	-0.59	0.56	0.39	0.28	0.73	1.0	0.95	-0.24		-0.98	0.47	0.73	1.0	1.0
Days Payables Outstanding	0.45	0.99	0.36	-0.52	0.58	0.6	0.98	0.99	0.45	0.58	-0.73	0.45	0.57	-0.45	-0.56	-0.23	-0.69	-0.98	-0.96	0.25	-0.98		-0.41	-0.76	-0.98	-0.98
Income Quality	-0.5	-0.44	0.01	-0.05	-0.67	-0.19	-0.48	-0.44	-0.42	-0.16	0.63	-0.47	-0.11	0.49	-0.12	0.27	0.15	0.48	0.47	0.24	0.47	-0.41		0.62	0.47	0.47
Roe	-0.54	-0.84	-0.21	0.04	-0.65	-0.17	-0.8	-0.84	-0.5	-0.16	1.0	-0.53	-0.13	0.54	0.36	0.12	0.3	0.73	0.86	0.09	0.73	-0.76	0.62		0.72	0.72
Ev To Operating Cash Flow	-0.57	-0.96	-0.46	0.56	-0.69	-0.63	-0.96	-0.96	-0.57	-0.6	0.71	-0.57	-0.58	0.57	0.38	0.29	0.73	1.0	0.95	-0.23	1.0	-0.98	0.47	0.72		1.0
Pe Ratio	-0.56	-0.96	-0.44	0.56	-0.69	-0.64	-0.96	-0.96	-0.56	-0.61	0.7	-0.56	-0.59	0.56	0.39	0.28	0.73	1.0	0.95	-0.24	1.0	-0.98	0.47	0.72	1.0

Click cells to compare fundamentals

Dianthus Therapeutics Account Relationship Matchups

Dianthus Therapeutics fundamentals Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Ptb Ratio	3.97	2.39	(14.11)	(0.53)	0.32	0.3
Book Value Per Share	61.03	52.42	(5.02)	(11.84)	32.77	38.91
Free Cash Flow Yield	(0.11)	(0.19)	(0.0408)	(1.23)	(0.69)	(0.72)
Operating Cash Flow Per Share	(24.68)	(23.32)	(2.88)	(7.76)	(7.15)	(7.51)
Capex To Depreciation	1.66	0.2	0.0163	0.95	0.31	0.29
Pb Ratio	3.97	2.39	(14.11)	(0.53)	0.32	0.3
Free Cash Flow Per Share	(26.01)	(23.47)	(2.89)	(7.79)	(7.17)	(7.53)
Roic	(0.43)	(0.64)	(0.6)	0.64	(0.28)	(0.3)
Net Income Per Share	(33.18)	(27.3)	(3.82)	(7.6)	(8.45)	(8.87)
Payables Turnover	0.25	0.66	0.53	1.49	0.13	0.14
Cash Per Share	62.99	54.22	15.41	20.15	33.71	46.19
Pocfratio	(9.83)	(5.38)	(24.58)	(0.81)	(1.45)	(1.53)
Capex To Operating Cash Flow	(0.0536)	(0.006248)	(0.003332)	(0.004782)	(0.002984)	(0.003133)
Pfcf Ratio	(9.33)	(5.34)	(24.5)	(0.81)	(1.45)	(1.52)
Days Payables Outstanding	556.91	693.83	245.56	2.9K	2.7K	2.5K
Income Quality	0.73	0.74	0.85	0.76	1.02	0.62
Roe	(0.54)	(0.52)	0.76	0.64	(0.26)	(0.27)
Ev To Operating Cash Flow	(8.69)	(4.47)	(23.81)	(0.31)	2.12	2.23
Pe Ratio	(7.31)	(4.6)	(18.57)	(0.83)	(1.23)	(1.29)
Return On Tangible Assets	(0.48)	(0.46)	(1.39)	(0.34)	(0.24)	(0.25)
Ev To Free Cash Flow	(8.25)	(4.44)	(23.73)	(0.31)	2.11	2.22
Earnings Yield	(0.14)	(0.22)	(0.0539)	(1.2)	(0.81)	(0.85)
Net Debt To E B I T D A	1.03	0.87	0.8	0.58	2.73	2.87
Current Ratio	10.62	13.26	1.75	9.97	18.42	19.35
Tangible Book Value Per Share	61.03	52.42	(5.02)	(11.84)	32.77	38.91
Graham Number	213.47	179.45	20.77	44.99	78.94	141.05
Shareholders Equity Per Share	61.03	52.42	(5.02)	(11.84)	32.77	38.91
Capex Per Share	1.32	0.15	0.009609	0.0371	0.0213	0.0203
Graham Net Net	54.21	47.77	7.99	(12.63)	31.73	36.78
Enterprise Value Over E B I T D A	(6.62)	(3.92)	(18.02)	(0.31)	1.62	1.7
Price Earnings Ratio	(7.31)	(4.6)	(18.57)	(0.83)	(1.23)	(1.29)
Price Book Value Ratio	3.97	2.39	(14.11)	(0.53)	0.32	0.3
Price Earnings To Growth Ratio	0.22	0.26	0.77	0.0131	(0.11)	(0.1)
Days Of Payables Outstanding	556.91	693.83	245.56	2.9K	2.7K	2.5K
Price To Operating Cash Flows Ratio	(9.83)	(5.38)	(24.58)	(0.81)	(1.45)	(1.53)
Price To Free Cash Flows Ratio	(9.33)	(5.34)	(24.5)	(0.81)	(1.45)	(1.52)
Ebt Per Ebit	0.96	0.93	0.95	1.0	0.9	1.06
Effective Tax Rate	(0.0808)	(0.1)	0.15	0.045	0.0405	0.0425

Currently Active Assets on Macroaxis

300825	Iat Automobile Technology
600666	Aurora Optoelectronics Co
000678	Xiangyang Automobile Bearing
603818	Qumei Furniture Group
002156	TongFu Microelectronics Co

When determining whether Dianthus Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Dianthus Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Dianthus Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Dianthus Therapeutics Stock:

How To Invest In Dianthus

Details

Is Dianthus Stock a good investment?

Details

What is Dianthus Therapeutics' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

For more detail on how to invest in Dianthus Stock please use our How to Invest in Dianthus Therapeutics guide.

You can also try the Financial Widgets module to easily integrated Macroaxis content with over 30 different plug-and-play financial widgets.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Dianthus Therapeutics. If investors know Dianthus will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Dianthus Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

7.22

Revenue Per Share

0.19

Quarterly Revenue Growth

1.351

Return On Assets

(0.19)

Return On Equity

(0.26)

The market value of Dianthus Therapeutics is measured differently than its book value, which is the value of Dianthus that is recorded on the company's balance sheet. Investors also form their own opinion of Dianthus Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Dianthus Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Dianthus Therapeutics' market value can be influenced by many factors that don't directly affect Dianthus Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Dianthus Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Dianthus Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Dianthus Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Dianthus Historical Financial Ratios

About Dianthus Financial Ratios Analysis

Dianthus Therapeutics Financial Ratios Chart

Price To Sales Ratio

Inventory Turnover

Intangibles To Total Assets

Dianthus Therapeutics fundamentals Correlations

Dianthus Therapeutics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Dianthus Therapeutics fundamentals Accounts

Currently Active Assets on Macroaxis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Price To Sales Ratio	Dividend Yield
Ptb Ratio	Days Sales Outstanding
Book Value Per Share	Free Cash Flow Yield
Invested Capital	Operating Cash Flow Per Share
Average Payables	Stock Based Compensation To Revenue
Capex To Depreciation	Pb Ratio
Ev To Sales	Free Cash Flow Per Share
Roic	Inventory Turnover
Net Income Per Share	Days Of Inventory On Hand
Payables Turnover	Sales General And Administrative To Revenue
Average Inventory	Research And Ddevelopement To Revenue
Capex To Revenue	Cash Per Share
Pocfratio	Interest Coverage
Payout Ratio	Capex To Operating Cash Flow
Pfcf Ratio	Days Payables Outstanding
Net Current Asset Value	Income Quality
Roe	Tangible Asset Value
Ev To Operating Cash Flow	Pe Ratio
Return On Tangible Assets	Ev To Free Cash Flow
Earnings Yield	Intangibles To Total Assets
Net Debt To E B I T D A	Current Ratio
Tangible Book Value Per Share	Receivables Turnover
Graham Number	Shareholders Equity Per Share
Debt To Equity	Capex Per Share
Graham Net Net	Average Receivables
Revenue Per Share	Interest Debt Per Share
Debt To Assets	Enterprise Value Over E B I T D A
Short Term Coverage Ratios	Price Earnings Ratio
Operating Cycle	Price Book Value Ratio
Price Earnings To Growth Ratio	Days Of Payables Outstanding
Dividend Payout Ratio	Price To Operating Cash Flows Ratio
Price To Free Cash Flows Ratio	Pretax Profit Margin
Ebt Per Ebit	Operating Profit Margin
Effective Tax Rate	Company Equity Multiplier
Long Term Debt To Capitalization	Total Debt To Capitalization
Return On Capital Employed	Debt Equity Ratio
Ebit Per Revenue	Quick Ratio
Dividend Paid And Capex Coverage Ratio	Net Income Per E B T
Cash Ratio	Cash Conversion Cycle
Operating Cash Flow Sales Ratio	Days Of Inventory Outstanding
Days Of Sales Outstanding	Free Cash Flow Operating Cash Flow Ratio
Cash Flow Coverage Ratios	Price To Book Ratio
Fixed Asset Turnover	Capital Expenditure Coverage Ratio
Price Cash Flow Ratio	Enterprise Value Multiple
Debt Ratio	Cash Flow To Debt Ratio
Price Sales Ratio	Return On Assets
Asset Turnover	Net Profit Margin
Gross Profit Margin	Price Fair Value
Return On Equity

Inventory Turnover	+ 1.0	Price To Sales Ratio
Pb Ratio	+ 1.0	Ptb Ratio
Free Cash Flow Per Share	+ 1.0	Operating Cash Flow Per Share
Inventory Turnover	+ 1.0	Ev To Sales
Net Income Per Share	+ 1.0	Free Cash Flow Per Share
Roe	+ 1.0	Roic

Days Of Inventory On Hand	- 1.0	Inventory Turnover
Days Of Inventory On Hand	- 1.0	Price To Sales Ratio
Days Of Inventory On Hand	- 0.99	Ev To Sales
Pe Ratio	- 0.98	Days Payables Outstanding
Ev To Operating Cash Flow	- 0.98	Days Payables Outstanding
Days Payables Outstanding	- 0.98	Pfcf Ratio